Women to Watch: determining clinical utility of genomic classifiers for tumor subtypes with Dr Maggie Cheang

Written by Maggie Cheang (Institute of Cancer Research, London, UK)

Maggie Cheang

As part of our ‘Women to Watch’ series on Oncology Central, we’re putting Dr Maggie Cheang into the spotlight.┬áDr Cheang is a Team Leader of the Integrative Genomic Analysis in Clinical Trials at the Institute of Cancer Research (London, UK). Her research focus is to develop genomics classifiers for tumor subtypes and to determine their clinical utility to predict sensitivity to therapeutic agents in Phase II and III clinical trials. Dr Cheang grew up in Vancouver, Canada and obtained her PhD in Pathology from the University of British Columbia (Canada). She then received the prestigious Canadian Cancer Society/Terry Fox Foundation...

To view this content, please register now for access

It's completely free